TBT1（Cat No.:I043590）is a selective small-molecule inhibitor designed to target specific proteins involved in the regulation of cell signaling and growth. It primarily focuses on inhibiting a key kinase or receptor that plays a role in the activation of cancer-related pathways. By disrupting these signaling pathways, TBT1 aims to reduce tumor cell proliferation and metastasis, making it a promising candidate for cancer therapy. Preclinical studies have shown potential efficacy in various cancer models. Ongoing research is focused on assessing TBT1’s safety, effectiveness, and potential use in combination therapies for treating solid tumors and hematological cancers.